Specific treatments for (pediatric) acute myeloid leukemia (AML) are lacking.
Standard treatments still include intensive myelosuppressive chemotherapy, which is unsatisfactory in terms of general toxicity, with the persistent risk of relapse due to the escape of quiescent leukemic cells to chemotherapy. Importantly, only 11 to 23 % of pediatric patients diagnosed with the most aggressive leukemia subtype harboring a known genetic rearrangement are designated as event-free survivors at 5 years.
Our invention relates to novel analogs of thioridazine, that lack a characteristic CNS toxicity of the parent molecule, for a targeted treatment of the most aggressive pediatric subtype of acute myeloid leukemia (t(6;11)AML featuring disease free survival at 5 years of only 11-23%).

TRL (Technology Readiness Level)

Lead Optimization/Preclinical

Inventors

Martina
Pigazzi

Claudia
Tregnago

Romeo
Romagnoli

Download the brochure

  • Novel Regulated Promoter for Gene Therapy

    Neuroinflammation, characterized by microglial cell-activation, plays a major role in the pathogenesis and progression of multiple neurodegenerative diseases, such as Lysosomal Storage Disorders and Alzheimer’s, severe human conditions currently lacking an effective treatment. Ex vivo gene therapy based on genetically[...]

  • Novel treatment to mitigate the Ectrodactyly-Ectodermal dysplasia- Clefting (EEC) associated blindness

    The Ectrodactyly-Ectodermal dysplasia-Clefting (EEC) syndrome is a rare genetic disorder due to mutations in the p63 gene and characterized by limb defects, orofacial clefting, ectodermal dysplasia, and ocular surface defects that lead to the loss of vision. Currently no specific[...]

  • Bicyclic peptides for targeted therapy against cancer

    Since inhibitors based on small molecules and macromolecules are not selective and potent enough, new compounds, including bicyclic peptides, have been developed in recent years. Bicyclic peptides are new generation therapeutic molecules which exhibit properties typical of monoclonal antibodies (high[...]

Subscribe to newsletter

Follow the activities promoted by UniSMART Foundation